Cardio-Oncology Updates

Home All News & Literature Highlights

The Role of Biomarkers to Evaluate Cardiotoxicity

Take a deep dive into the current evidence regarding biomarkers for the detection of cardiovascular toxicity during and after cancer therapy, including the use of cardiac troponin, natriuretic peptides, and serum biomarkers.

Current Treatment Options in Oncology

Class Categories

Immune Checkpoint Inhibitors

Kinase Inhibitors

HER2-Targeted Therapies

Novel Immunotherapies (CAR-T, BiTE)

CARDIO-ONCOLOGY BASICS

What is Cardio-Oncology?

Link Between Cancer, Treatment, and Heart Disease

Cardio-Oncology Standards of Care

CV Evaluation of Patients Before and During Cancer Therapy

Cancer Treatment–Related Cardiotoxicity

Breast Cancer Drugs and Cardiotoxicity

Cardio-Oncology Basics: Conclusions

Meet the Faculty

Resources

General Cardio-Oncology The Cancer Patient and Cardiology

General Cardio-Oncology The Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio‐Oncology Council of the European Society of Cardiology (ESC)

General Cardio-Oncology Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools From the Cardio-Oncology Study Group of the Heart Failure Association of the European Society

General Cardio-Oncology NCCN Clinical Practice Guidelines in Oncology: Survivorship Version 2.2020

General Cardio-Oncology Cardiovascular and Cancer Risk: The Role of Cardio-Oncology

Videos

Novel Immunotherapies Managing Cardiotoxicity Associated With BiTE Therapy: A Case Study

HER2-Targeted Therapies Monitoring and Management Strategies for HER2-Targeted Therapy–Associated Cardiotoxicity

Immune Checkpoint Inhibitors Managing Cardiotoxicity Associated With Immune Checkpoint Inhibitor Therapy

Kinase Inhibitors Managing Ibrutinib-Associated Cardiotoxicity in CLL: A Case Study

HER2-Targeted Therapies HER2-Targeted Therapies: Cardiotoxicity Incidence